Search Results - "Chrysavgi, Lalayanni"
-
1
Aplastic anemia and paroxysmal nocturnal hemoglobinuria in children and adults in two centers of Northern Greece
Published in Frontiers in oncology (10-11-2022)“…Bone marrow failure (BMF) syndromes are a group of various hematological diseases with cytopenia as a main common characteristic. Given their rarity and…”
Get full text
Journal Article -
2
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
Published in Frontiers in oncology (2023)“…The analysis of the immunogenetic background of multiple myeloma (MM) has proven key to understanding disease ontogeny. However, limited information is…”
Get full text
Journal Article -
3
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
Published in Frontiers in medicine (11-10-2023)“…Given the limited real-world data of caplacizumab, our multicenter real-world study was designed to assess the safety and efficacy of caplacizumab in immune…”
Get full text
Journal Article -
4
Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing
Published in Thrombosis update (01-05-2021)“…ADAMTS13 (A Disintegrin and Metalloprotease with ThromboSpondin type 1 motifs) activity is a key tool in differential diagnosis of thrombotic microangiopathies…”
Get full text
Journal Article -
5
An outbreak of Burkholderia cepacia bacteremia in hospitalized hematology patients selectively affecting those with acute myeloid leukemia
Published in American journal of infection control (01-04-2013)“…Background Burkholderia cepacia complex (Bcc) is a group of common environmental bacteria that preferentially colonize and infect patients with cystic fibrosis…”
Get full text
Journal Article -
6
Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes
Published in Leukemia & lymphoma (10-11-2022)“…Opposing acute lymphoblastic leukemia, sparse data about AYAs with acute myeloid leukemia (AML) is available. Overall, 125 AYAs (age 10-35 years) treated…”
Get full text
Journal Article -
7
Outcomes of Patients with Hematologic Malignancies and COVID-19: Perspective of a Large Hematology Center in Greece
Published in Blood (23-11-2021)“…The emergence of SARS-CoV-2, as of July 2021 has affected 469,042 individuals and accounted for 12,851 deaths nationally in Greece, according to WHO database…”
Get full text
Journal Article -
8
Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis
Published in Blood (15-11-2022)Get full text
Journal Article -
9
Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment
Published in Current problems in cancer (01-06-2019)“…Blinatumomab, a bispecific T-cell engager antibody construct targeting CD19, has been shown to improve the outcome in patients with relapsed and/or refractory…”
Get full text
Journal Article -
10
Allogeneic Hematopoietic Cell Transplantation with Myeloablative Conditioning Regimen of Reduced Toxicity Is Associated with Favorable Survival in Patients with Secondary Acute Myeloid Leukemia
Published in Blood (05-11-2020)“…Background: Secondary or treatment-related acute myeloid leukemia (sAML) is associated with poor outcomes. Although allogeneic hematopoietic cell…”
Get full text
Journal Article -
11
-
12
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment
Published in Blood (15-11-2022)Get full text
Journal Article -
13
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study
Published in Annals of hematology (01-10-2018)“…The role of total body irradiation (TBI) in allogeneic hematopoietic stem cell transplantation (HCT) for adult acute lymphoblastic leukemia (ALL) remains…”
Get full text
Journal Article -
14
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML
Published in Clinical lymphoma, myeloma and leukemia (01-04-2022)“…Therapy related acute myeloid leukemia (tAML) and secondary AML after an antecedent hematologic disorder (sAML-AHD) are often addressed together, blurring any…”
Get full text
Journal Article -
15
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Published in American journal of hematology (01-11-2024)“…Prior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and…”
Get full text
Journal Article -
16
Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘Powerful’ Study
Published in Blood (05-11-2020)“…Introduction: Pomalidomide (POM) plus low-dose dexamethasone (POM/LoDex) is a standard of care for patients with relapsed/refractory multiple myeloma (RRMM),…”
Get full text
Journal Article -
17
Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis
Published in Cancers (07-07-2023)“…(1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T cell and gene therapy, constitute…”
Get full text
Journal Article -
18
Nelarabine-associated reversible Guillain-Barré–like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma
Published in Current problems in cancer (01-03-2017)“…Nelarabine is a purine analogue used for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic…”
Get full text
Journal Article -
19
Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes
Published in Blood (13-11-2019)“…Introduction: ADAMTS13 (A Disintegrin and Metalloprotease with ThromboSpondin type 1 repeats) activity remains a key tool in differential diagnosis of…”
Get full text
Journal Article -
20
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
Published in The Lancet. Haematology (01-12-2023)“…BACKGROUNDSymptoms of anaemia due to clinically significant extravascular haemolysis can affect patients with paroxysmal nocturnal haemoglobinuria (PNH)…”
Get full text
Journal Article